Grant: Idea to Innovation
McMaster University
$125,000.00
Zwitterionic in situ-gelling hydrogel-based bioinks for tissue regeneration applications
EF 2022-23
Résumé
Despite the tremendous promise of 3D bioprinting for revolutionizing our ability to regenerate diseased tissues and/or create cell-based therapeutics for managing chronic diseases, the rapid development of 3D bioprinting technologies has greatly outpaced the development of new functional commercially-available bioinks to leverage those technologies. In particular, the availability of a bioink that can enable free-form bioprinting using multiple types of 3D printers and meet the key physical and biological requirements of a functional tissue scaffold (i.e. targeted mechanics, tunable degradation, well-defined porosity, cell adhesivity, and anti-fibrotic properties) is essential to address key translational challenges in tissue engineering and cell therapy. Toward meeting this challenge, we have developed an in situ-gelling zwitterionic hydrogel based on mixing hydrazide and aldehyde and/or ketone functionalized pre-polymers to form a reversible hydrazone-crosslinked gel network. These hydrogels can facilitate ultra-fast gelation upon mixing (<1 s), highly tunable degradation times (ranging from a few days to several months), extremely high lubricity (beneficial for 3D printing cartilage for joint regeneration), very low cell/protein adsorption, anti-fibrotic tissue responses, and a capacity to support both the viability and expansion of encapsulated cells, a suite of properties highly relevant to a 3D bioink. While these materials have already attracted interest from potential company partners in the 3D bioprinting industry, proof-of-concept demonstrations around practically implementing our in situ gelation crosslinking chemistry on commercial 3D printers to achieve required shape fidelities and mechanics, printing clinically-relevant primary human cells or stem cells, and ensuring the scalable manufacturing of chemically pure and biologically inert bioink components are required prior to investment being feasible. The work proposed in this I2I grant is designed to answer these key proof-of-concept questions, aiming to produce at least one 3D bioink "kit" that could be licensed for distribution and/or internal development use at one or more leading 3D printing companies by the end of the I2I project period.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
570996-2022
Name nom
Hoare, Todd TR
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2022
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Installment
inst:1
Partie
1
Nb partie
1
Application title
Zwitterionic in situ-gelling hydrogel-based bioinks for tissue regeneration applications
Application summary
Despite the tremendous promise of 3D bioprinting for revolutionizing our ability to regenerate diseased tissues and/or create cell-based therapeutics for managing chronic diseases, the rapid development of 3D bioprinting technologies has greatly outpaced the development of new functional commercially-available bioinks to leverage those technologies. In particular, the availability of a bioink that can enable free-form bioprinting using multiple types of 3D printers and meet the key physical and biological requirements of a functional tissue scaffold (i.e. targeted mechanics, tunable degradation, well-defined porosity, cell adhesivity, and anti-fibrotic properties) is essential to address key translational challenges in tissue engineering and cell therapy. Toward meeting this challenge, we have developed an in situ-gelling zwitterionic hydrogel based on mixing hydrazide and aldehyde and/or ketone functionalized pre-polymers to form a reversible hydrazone-crosslinked gel network. These hydrogels can facilitate ultra-fast gelation upon mixing (<1 s), highly tunable degradation times (ranging from a few days to several months), extremely high lubricity (beneficial for 3D printing cartilage for joint regeneration), very low cell/protein adsorption, anti-fibrotic tissue responses, and a capacity to support both the viability and expansion of encapsulated cells, a suite of properties highly relevant to a 3D bioink. While these materials have already attracted interest from potential company partners in the 3D bioprinting industry, proof-of-concept demonstrations around practically implementing our in situ gelation crosslinking chemistry on commercial 3D printers to achieve required shape fidelities and mechanics, printing clinically-relevant primary human cells or stem cells, and ensuring the scalable manufacturing of chemically pure and biologically inert bioink components are required prior to investment being feasible. The work proposed in this I2I grant is designed to answer these key proof-of-concept questions, aiming to produce at least one 3D bioink "kit" that could be licensed for distribution and/or internal development use at one or more leading 3D printing companies by the end of the I2I project period.